Demand for drugs drives up profits at Novartis

Novartis has revealed strong first-half results, fuelled by demand for its hypertension, osteoporosis and asthma drugs.

Europe's third-largest pharmaceuticals company says operating profit rose 7% in the first-half as demand for its hypertension treatment Diovan accelerated.